BT
Therapeutic Areas
NewAmsterdam Pharma Company Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Obicetrapib | Heterozygous Familial Hypercholesterolemia (HeFH) and/or established Atherosclerotic Cardiovascular Disease (ASCVD) | Phase 3 |
| NA-0111 | Undisclosed metabolic indication | Preclinical |
Leadership Team at NewAmsterdam Pharma Company
JK
John Kastelein
Chief Scientific Officer and Founder
MD
Michael Davidson
Chief Executive Officer
ES
Evan Stein
Chief Medical Officer and Founder
BG
Brenton G. Ahrens
Chief Financial Officer
MD
Menno de Vries
Chief Operating Officer
CK
Chris K. Lee
General Counsel
AV
Annemieke van Vuuren
Chief Human Resources Officer
PJ
Patrick J. McEnany
Chairman of the Board of Directors
JE
James E. Flynn
Director
AE
Andrew ElBardissi
Director